ARCHIVES

Program Monitors Resistance In Antimicrobial And Antifungal Therapies for Cancer Patients

This article is from The Cancer Letter archive.

Vol. 25 No. 11 | November 29, 2002

Download PDF Visit The Full Archive

Related Articles

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

FDA Simplifies Reporting Of Adverse Events

June 18, 1993

NCAB Settles PDQ Controversy; More CCOP Awards May Be Made, Center Guidelines Revisions Coming

October 7, 1983

In Brief: Guide Is Late, So RFP Deadline Extended; Real Cancer Mortality Increase Was .7%

January 28, 1977

Trimodality Therapy Improves Survival In Early Disease

January 27, 2006

New Breast Cancer Therapies Move Into General Practice; Fisher, Miami Plan Segmental Trials

February 13, 1976